neutropen
fever
one
defin
condit
oncolog
critic
care
neutropen
fever
defin
singl
temperatur
higher
c
sustain
temperatur
greater
c
h
presenc
absolut
neutrophil
count
anc
less
cellsmm
though
mani
center
guidelin
use
anc
cutoff
less
cellsmm
exceedingli
common
patient
receiv
cytotox
chemotherapi
neutropen
fever
medic
emerg
requir
urgent
initi
broadspectrum
antibiot
oncolog
patient
receiv
myelosuppress
chemotherapi
risk
develop
neutropenia
opportunist
infect
profound
neutropenia
lifethreaten
infecti
complic
commonli
seen
patient
hematolog
malign
occur
aplasia
engraft
patient
receiv
hematopoiet
stem
cell
transplant
hsct
diseaserel
treatmentinduc
cytopenia
hematolog
malign
patient
mani
potenti
caus
fever
neutropen
host
infecti
noninfecti
fever
must
presum
infecti
origin
potenti
infecti
agent
sourc
infect
legion
includ
virus
bacteria
fungu
viral
pathogen
includ
respiratori
virus
eg
respiratori
syncyti
viru
rhinoviru
adenoviru
coronaviru
influenza
parainfluenza
reactiv
de
novo
herp
virus
eg
herp
simplex
cytomegaloviru
epsteinbarr
viru
mani
potenti
candid
bacteri
infect
may
aris
gut
transloc
oral
mucos
transloc
infect
indwel
vascular
cathet
skin
soft
tissu
infect
pneumonia
urinari
sourc
fungal
infect
typic
aris
gut
transloc
fungal
pneumonia
eg
aspergillosi
vascular
cathet
drug
fever
tumor
fever
common
exampl
noninfecti
fever
diagnos
exclus
neutropen
fever
occur
patient
solid
tumor
receiv
cytotox
chemotherapi
patient
receiv
chemotherapi
hematolog
malign
undergo
hsct
adult
hospit
cancerrel
neutropenia
total
cost
billion
inhospit
mortal
patient
admit
neutropen
fever
nearli
increas
hospit
mortal
rate
patient
leukemia
admit
neutropen
fever
bacteremia
document
neutropen
fever
patient
wherea
past
gramneg
organ
commonli
cultur
gramposit
organ
includ
staphylococci
enterococci
streptococci
current
commonli
isol
bacteria
tabl
shift
presum
due
increas
use
longterm
indwel
vascular
cathet
may
also
affect
increas
use
prophylaxi
gram
though
gramposit
infect
common
gramneg
infect
confer
higher
risk
mortal
fungal
infect
particularli
candida
aspergillu
also
frequent
especi
patient
prolong
profound
neutropenia
respiratori
virus
isol
approxim
patient
despit
best
effort
caus
organ
identifi
case
neutropen
fever
sepsi
recent
defin
lifethreaten
organ
dysfunct
caus
dysregul
host
respons
infect
premium
place
identif
organ
dysfunct
use
either
sequenti
organ
failur
assess
sofa
score
quick
sofa
qsofa
score
presenc
organ
dysfunct
set
suspect
proven
infect
suffici
diagnos
sepsi
tabl
septic
shock
defin
need
vasopressor
maintain
mean
arteri
pressur
map
mmhg
serum
lactat
mmoll
despit
adequ
volum
resuscit
specif
consensu
definit
neutropen
sepsi
sepsi
occur
presenc
neutropenia
evid
organ
dysfunct
includ
elev
lactat
presenc
neutropenia
treat
potenti
indic
sepsi
reliabl
data
incid
neutropen
sepsi
neutropen
septic
shock
estim
patient
neutropen
fever
develop
sepsi
patient
neutropen
fever
progress
septic
shock
among
neutropen
allogen
hsct
patient
approxim
develop
sever
sepsi
engraft
period
cytotox
chemotherapi
cytotox
radiat
whether
given
antitumor
agent
condit
regimen
hsct
induc
neutropenia
injur
destroy
hematopoiet
precursor
cell
within
bone
marrow
well
injur
bone
marrow
structur
circul
neutropenia
develop
rapidli
myelosuppress
therapi
depend
chemotherapi
employ
circul
neutrophil
white
blood
cell
may
also
damag
destroy
caus
rapid
leukopenia
regimen
affect
marrow
agent
injur
progenitor
cell
primit
stem
cell
repopul
progenitor
cell
wherea
agent
injur
cell
marrow
normal
patient
local
infect
neutrophil
rapidli
recruit
onset
focal
infect
essenti
microbi
kill
infect
control
neutropen
fever
neutropen
sepsi
histor
thought
variant
nonneutropen
fever
sepsi
without
intact
immun
system
akin
fire
without
firefight
howev
increas
data
suggest
pathophysiolog
neutropen
patient
much
complic
simpli
uncontrol
infect
addit
key
role
respons
local
infect
eg
pneumonia
sepsi
neutrophil
rapidli
recruit
organ
lung
kidney
liver
thought
contribut
tissu
damag
organ
dysfunct
neutrophil
also
contribut
resolut
injuri
tissu
repair
well
regul
adapt
immun
respons
thu
neutropen
patient
defici
immedi
respons
infect
also
alter
physiolog
regard
develop
system
inflamm
sepsi
regul
immun
respons
injuri
tissu
repair
increasingli
unclear
whether
neutropen
sepsi
organ
damag
sequela
diseas
nonneutropen
sepsi
cytotox
chemotherapi
select
neutropen
patient
also
lymphopen
thrombocytopen
anem
lymphocyt
includ
cell
b
cell
natur
killer
nk
cell
protean
role
immun
system
broad
effect
respons
infect
septic
physiolog
cell
also
drastic
reduc
cytotox
chemotherapi
lymphopenia
associ
increas
risk
death
ad
complex
kinet
count
recoveri
engraft
vari
reconstitut
cell
line
happen
simultan
though
total
effect
lymphopenia
pathophysiolog
neutropen
fever
infect
remain
fulli
determin
patient
neutropen
sepsi
differ
cytokin
profil
patient
nonneutropen
sepsi
neutropen
patient
higher
level
gcsf
nonneutropen
patient
monocyt
also
dysfunct
neutropen
sepsi
evid
deactiv
monocyt
peripher
blood
also
deactiv
differenti
pulmonari
macrophag
patient
neutropen
sepsi
implic
pancytopenia
respons
infect
extend
beyond
white
blood
cell
neutropen
patient
thrombocytopen
platelet
increasingli
recogn
play
import
role
immun
respons
thrombocytopenia
associ
poor
outcom
critic
ill
includ
sepsi
addit
secret
mediat
regul
inflamm
platelet
interact
neutrophil
monocyt
play
vital
role
defens
bacteri
viral
fungal
infect
via
format
neutrophil
extracellular
trap
net
platelet
also
play
role
develop
resolut
organ
failur
inflammatori
state
includ
sepsi
particular
thrombocytopenia
demonstr
potenti
lung
injuri
platelet
may
play
role
pathophysiolog
acut
kidney
injuri
role
thrombocytopenia
infect
remain
incomplet
elucid
seem
clear
thrombocytopenia
import
factor
pathophysiolog
neutropen
infect
organ
system
relev
neutropen
infect
also
affect
cytotox
chemotherapi
import
injuri
mucos
barrier
intestin
tract
disrupt
barrier
occur
throughout
gastrointestin
gi
tract
creat
portal
enter
pathogen
includ
bacteria
yeast
enter
bloodstream
import
sourc
gramposit
gramneg
fungal
infect
neutropen
patient
respiratori
system
also
affect
neutropenia
pulmonari
macrophag
known
qualit
dysfunct
neutropen
sepsi
quantit
cell
count
alveolar
macrophag
lymphocyt
neutrophil
decreas
neutropenia
neutropenia
also
appear
advers
affect
lung
repair
injuri
taken
togeth
data
strongli
support
hypothesi
neutropen
sepsi
significantli
differ
pathophysiolog
nonneutropen
sepsi
defin
diagnosi
neutropen
fever
requir
singl
temperatur
higher
c
sustain
temperatur
greater
c
h
presenc
neutropenia
patient
asymptomat
presenc
neutropen
fever
mani
describ
nonspecif
symptom
eg
cough
anorexia
nausea
fatigu
dizzi
myalgia
confus
behavior
chang
patient
may
also
present
respiratori
symptom
cough
short
breath
sinu
pain
drainag
abdomin
symptom
pain
diarrhea
fewer
half
patient
feel
feverish
shiver
rigor
present
hospit
delay
one
studi
suggest
mean
delay
present
h
nearli
patient
delay
present
h
though
neutropen
patient
higher
fever
nonneutropen
patient
associ
peak
temperatur
mortal
hypothermia
neutropen
sepsi
associ
wors
outcom
neutropen
patient
septic
shock
tend
frequent
posit
blood
cultur
fungal
infect
multidrugresist
bacteri
infect
higher
mortal
rate
immunocompet
patient
compar
nonneutropen
patient
patient
neutropen
sepsi
higher
rate
shock
higher
risk
sustain
acut
kidney
injuri
earli
recognit
neutropen
fever
essenti
regardless
whether
neutropen
patient
hospit
frequent
temperatur
check
essenti
detect
fever
outpati
must
particularli
educ
import
monitor
temperatur
similarli
intervent
might
mask
fever
eg
antipyret
acetaminophen
gener
avoid
neutropen
patient
clinician
awar
intervent
eg
steroid
continu
renal
replac
therapi
may
suppress
fever
fever
detect
blood
cultur
obtain
without
delay
antibiot
initi
quickli
possibl
diagnost
measur
must
interfer
time
administr
antibiot
comprehens
physic
exam
perform
may
uncov
potenti
sourc
infect
eg
mouth
sore
skin
lesion
pulmonari
find
abdomin
tender
pain
blood
cultur
essenti
evalu
neutropen
patient
fever
minimum
two
set
blood
cultur
drawn
upon
present
current
recommend
suggest
obtain
two
set
cultur
includ
peripher
blood
cultur
cultur
central
venou
cathet
present
addit
laboratori
studi
present
includ
complet
blood
count
differenti
electrolyt
marker
renal
hepat
function
creatinin
blood
urea
nitrogen
transaminas
depend
clinic
scenario
strong
consider
given
obtain
arteri
blood
ga
coagul
studi
lactat
level
lactat
particular
potenti
interest
elev
level
may
help
detect
earli
evid
sepsisinduc
malperfus
microbiolog
studi
target
toward
patientspecif
indic
exampl
urinari
symptom
abnorm
urinalysi
prompt
urin
cultur
diarrhea
especi
patient
treat
antibiot
prompt
evalu
clostridium
difficil
coliti
fungal
marker
galactomannan
betadglucan
may
use
patient
respiratori
symptom
abnorm
chest
imag
evalu
test
respiratori
virus
sputum
cultur
symptomguid
imag
studi
compris
import
part
evalu
neutropen
fever
chest
comput
tomographi
ct
scan
perform
patient
respiratori
symptom
potenti
asymptomat
patient
cryptic
fever
plain
chest
radiograph
limit
util
popul
routin
obtain
lieu
ct
scan
sinu
head
abdomin
imag
perform
indic
use
nuclear
medicin
techniqu
fdgpet
ct
identifi
foci
infect
febril
neutropenia
describ
util
techniqu
yet
proven
remain
impract
current
clinic
use
note
respiratori
symptom
andor
presenc
abnorm
chest
imag
prompt
evalu
respiratori
infect
case
done
noninvas
bronchoscopi
may
indic
patient
benefit
potenti
diagnosi
must
weigh
risk
requir
endotrach
intub
bronchoscopi
abdomin
symptom
pain
diarrhea
lead
consider
neutropen
enterocol
also
known
typhliti
incomplet
understood
condit
ileocolon
inflamm
lead
intestin
necrosi
perfor
associ
high
mortal
rate
diagnosi
requir
presenc
neutropenia
bowel
wall
thicken
mm
mm
longitudin
distanc
fever
c
abdomin
pain
specif
diagnosi
elus
mani
patient
diagnost
step
repeat
sourc
found
fever
persist
h
repeat
blood
cultur
repeat
expand
imag
studi
may
provid
addit
diagnost
inform
risk
stratif
essenti
part
diagnosi
inform
immedi
manag
multin
associ
support
care
cancer
mascc
score
tabl
develop
predict
patient
neutropen
fever
may
safe
treat
outpati
score
identifi
standard
risk
patient
wherea
score
indic
highrisk
patient
addit
criteria
outpati
treatment
enumer
heinz
et
al
focu
sign
clinic
social
stabil
particular
emphasi
place
expect
good
adher
oral
medic
adequ
social
support
patient
live
alon
abil
present
hospit
within
min
note
mascc
score
limit
util
predict
either
risk
critic
ill
icu
outcom
factor
influenc
risk
stratif
includ
depth
durat
neutropenia
anc
cellsmm
day
durat
respect
marker
highrisk
patient
accordingli
neutropen
modifi
patient
hematolog
malign
statu
post
hsct
almost
alway
higher
risk
patient
becom
neutropen
cours
cyclic
treatment
solid
malign
comorbid
condit
also
integr
clinic
risk
assess
pharmacolog
prophylaxi
neutropen
patient
neutropen
fever
develop
due
high
risk
infect
neutropenia
mani
center
provid
routin
antimicrobi
prophylaxi
patient
deem
high
risk
infect
expect
prolong
period
profound
neutropenia
eg
anc
cellsmm
day
rational
antibacteri
prophylaxi
reduc
risk
gramneg
infect
streptococc
infect
oral
mucos
highrisk
patient
current
guidelin
suggest
antibacteri
prophylaxi
fluoroquinolon
ciprofloxacin
levofloxacin
latter
prefer
sever
mucos
anticip
antifung
prophylaxi
yeast
recommend
highrisk
patient
hsct
chemotherapi
leukemia
fluconazol
itraconazol
voriconazol
posaconazol
echinocandin
caspofungin
micafungin
antimold
aspergillu
prophylaxi
voriconazol
posaconazol
recommend
patient
undergo
chemotherapi
leukemia
patient
anticip
prolong
neutropenia
prior
invas
mold
infect
antivir
prophylaxi
acyclovir
valacyclovir
recommend
patient
seroposit
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
seroposit
hsct
patient
final
leukemia
hsct
patient
receiv
prophylaxi
pneumocysti
jirovecii
pneumonia
prophylact
antimicrobi
may
lessen
elimin
risk
infect
neutropen
thu
patient
caregiv
must
remain
vigil
develop
fever
moreov
attent
must
paid
prophylact
regimen
affect
choic
empir
antibiot
neutropen
fever
neutropen
fever
medic
emerg
appropri
empir
antibiot
must
start
without
delay
within
min
present
data
suggest
even
delay
antibiot
administr
beyond
min
associ
increas
mortal
note
desir
obtain
blood
cultur
possibl
antibiot
initi
long
delay
antibiot
administr
diagnost
maneuv
attempt
antibiot
initi
empir
antibiot
must
cover
common
organ
discuss
pseudomona
aeruginosa
staphylococcu
aureu
streptococc
speci
also
tailor
accord
prior
patientspecif
cultur
data
institut
epidemiolog
appropri
empir
antibiot
includ
antipseudomon
penicillin
eg
piperacillin
tazobactam
antipseudomon
cephalosporin
eg
cefepim
carbapenem
imipenem
meropenem
data
suggest
improv
outcom
prolong
antibiot
infus
time
though
data
requir
confirm
fluoroquinolon
frequent
use
prophylact
therapi
neutropenia
use
empir
monotherapi
neutropen
fever
due
possibl
resist
though
gramposit
organ
common
caus
neutropen
fever
vancomycin
routin
indic
ad
presenc
suspect
catheterrel
infect
soft
tissu
infect
oral
mucos
radiograph
proven
pneumonia
known
colon
resist
gramposit
organ
eg
methicillinresist
staphylococcu
aureu
penicillinresist
streptococcu
hemodynam
instabl
use
combin
antibiot
regimen
defin
dual
gramneg
coverag
antipseudomon
betalactam
aminoglycosid
neutropen
fever
controversi
though
studi
suggest
mortal
benefit
combin
antibiot
consist
find
metaanalys
shown
benefit
addit
aminoglycosid
betalactam
higher
risk
renal
failur
combin
therapi
accordingli
current
guidelin
manag
neutropen
fever
sepsi
recommend
monotherapi
antipseudomon
betalactam
unless
otherwis
dictat
circumst
patient
allergi
presenc
resist
organ
refractori
hemodynam
instabl
note
howev
recommend
preclud
use
vancomycin
antifung
direct
combin
therapi
target
gramneg
bacteria
even
appropri
antibiot
fever
neutropen
patient
typic
persist
median
day
thu
ongo
fever
unless
accompani
clinic
instabl
necessarili
view
evid
failur
antibiot
therapi
patient
persist
recurr
fever
day
modif
antibiot
regimen
reason
especi
guid
new
chang
clinic
data
earlier
antibiot
escal
necessari
patient
commonli
patient
hemodynam
instabl
face
hemodynam
instabl
vancomycin
ad
alreadi
part
regimen
addit
antipseudomon
cephalosporin
penicillin
escal
carbapenem
eg
meropenem
strong
consider
given
addit
aminoglycosid
fluoroquinolon
aztreonam
drugresist
multidrugresist
mdr
organ
increas
problem
neutropen
infect
vancomycinresist
enterococcu
vre
bacteremia
affect
substanti
portion
patient
induct
therapi
leukemia
hsct
associ
significantli
wors
outcom
earli
treatment
agent
activ
vre
linezolid
daptomycin
may
improv
outcom
predict
model
develop
assist
earli
identif
patient
might
benefit
earli
initi
antibiot
activ
vre
similarli
mdr
gramneg
infect
particularli
carbapenemresist
enterobacteriacea
associ
high
mortal
rate
especi
among
allogen
hsct
patient
success
treatment
infect
requir
earli
use
multidrug
antibiot
regimen
typic
includ
aminoglycosid
carbapenem
polymyxin
use
surveil
rectal
cultur
perform
pretranspl
weekli
hsct
identifi
patient
mdr
infect
allow
immedi
initi
antibiot
therapi
target
mdr
organ
may
result
better
outcom
fungal
pathogen
constant
threat
neutropen
patient
consider
must
given
use
antifung
agent
patient
neutropen
fever
gener
antifung
therapi
initi
set
persist
fever
day
appropri
antibacteri
appropri
antifung
activ
mold
especi
aspergillosi
exampl
includ
liposom
amphotericin
caspofungin
voriconazol
though
data
robust
favor
former
two
fluconazol
use
empir
therapi
increas
number
neutropen
patient
antifung
prophylaxi
voriconazol
prior
develop
fever
util
chang
antifung
agent
upon
fever
develop
set
unclear
antifung
strongli
consid
earli
therapi
patient
hemodynam
unstabl
advent
multidrugresist
organ
antibiot
stewardship
increasingli
import
even
neutropen
patient
optimum
durat
antimicrobi
therapi
neutropen
patient
whether
antimicrobi
may
safe
deescal
face
clinic
stabil
ongo
area
investig
one
random
control
trial
suggest
empir
antibiot
may
safe
discontinu
patient
defervesc
remain
afebril
h
regardless
whether
neutrophil
recoveri
occur
anoth
recent
paper
suggest
safe
withhold
antibacteri
therapi
children
neutropen
fever
infect
respiratori
viru
proven
neither
tactic
becom
standard
care
highlight
increasingli
realiz
import
antibiot
stewardship
even
neutropen
patient
hematopoiet
growth
factor
may
consid
select
case
neutropen
fever
shown
shorten
durat
neutropenia
impact
mortal
accord
due
lack
proven
mortal
benefit
current
guidelin
recommend
routin
use
hematopoiet
growth
factor
neutropen
fever
neutropen
sepsi
granulocyt
transfus
use
support
patient
neutropenia
prevent
infect
help
treat
establish
infect
studi
perform
evalu
intervent
studi
avail
small
two
recent
cochran
metaanalys
examin
use
granulocyt
transfus
neutropen
patient
prevent
treat
infect
respect
conclud
insuffici
evid
determin
whether
granulocyt
transfus
confer
mortal
benefit
earli
appropri
administr
antimicrobi
essenti
prevent
death
neutropen
fever
neutropen
sepsi
good
outcom
also
depend
success
manag
hemodynam
derang
organ
failur
sepsi
intens
care
unit
icu
bestsuit
locat
care
neutropen
patient
sepsi
septic
shock
earlier
icu
admiss
associ
improv
surviv
rate
recent
guidelin
publish
manag
sepsi
septic
shock
guidelin
also
applic
manag
neutropen
sepsi
key
point
includ
initi
resuscit
least
mlkg
intraven
crystalloid
addit
fluid
resuscit
indic
use
norepinephrin
firstlin
vasopressor
target
mean
arteri
pressur
mm
hg
either
vasopressin
epinephrin
may
ad
respons
norepinephrin
inadequ
may
benefit
use
balanc
crystalloid
solut
lactat
ringer
plasmalyt
rather
normal
salin
sourc
control
obtain
possibl
though
occasion
abscess
may
present
feasibl
drain
commonli
indwel
central
venou
cathet
address
sourc
infect
hemodynam
unstabl
patient
suspect
cathet
infect
earli
cathet
remov
associ
improv
surviv
accordingli
infect
potenti
infect
cathet
remov
without
delay
patient
neutropenia
sepsi
high
risk
develop
multiorgan
failur
particularli
acut
respiratori
distress
syndrom
ard
use
noninvas
ventil
immunosuppress
patient
hypoxem
respiratori
failur
increasingli
controversi
heat
humidifi
highflow
oxygen
may
better
option
patient
intub
low
tidal
volum
ventil
use
maxim
lung
protect
minim
ventilatorinduc
lung
injuri
adjunct
neuromuscular
blockad
prone
posit
use
patient
moder
sever
ard
mortal
patient
develop
ard
context
remain
high
outcom
improv
attent
best
practic
mechan
ventil
essenti
algorithm
empir
manag
neutropen
fever
found
fig
risk
neutropen
fever
neutropen
sepsi
resolv
bone
marrow
recov
neutrophil
count
return
normal
treat
appropri
neutropen
fever
common
predict
manag
complic
cytotox
therapi
hsct
neutropen
sepsi
continu
confer
poor
prognosi
recent
data
suggest
approxim
mortal
rate
patient
hematolog
malign
develop
septic
shock
predictor
mortal
includ
sepsi
allogen
hsct
presenc
graft
vs
host
diseas
respiratori
failur
requir
mechan
ventil
posit
blood
cultur
cardiac
failur
renal
failur
hepat
failur
younger
age
year
presenc
neutropen
enterocol
associ
improv
surviv
encouragingli
surviv
neutropen
sepsi
septic
shock
appear
improv
still
wors
nonneutropen
septic
patient
emerg
multidrugresist
organ
major
concern
urgent
need
novel
antibiot
address
threat
along
line
addit
work
need
done
identifi
patient
antibiot
therapi
safe
deescal
pathophysiolog
neutropen
sepsi
requir
studi
effort
made
facilit
earlier
diagnosi
identif
pathogen
neutropen
patient
final
neutropen
sepsi
studi
specif
separ
entiti
normal
sepsi
efficaci
intervent
confirm
specif
popul
